690 elite

Manufactured by GE Healthcare

Sourced in United States

The 690 Elite is a laboratory equipment product from GE Healthcare. It is designed to perform core functions for laboratory applications. Detailed product information is not available for this unbiased, factual description.

Automatically generated - may contain errors

Lab products found in correlation

Ge discovery pet ct 690, by GE Healthcare (2 mentions) Discovery pet ct 690, by GE Healthcare (2 mentions) Biograph 40 truepoint pet ct, by Siemens (1 mentions) Biograph truepoint 40, by Siemens (1 mentions) Biograph sensation 16, by Siemens (1 mentions) Gmp grade dota toc, by Horiba (1 mentions) Discovery 690, by GE Healthcare (1 mentions)

Close spelling variants of this product

Discovery PET/CT 690 Elite scanner GE Discovery Elite 690 690 Elite PET/CT scanners Discovery 690 Elite

6 protocols using 690 elite

Predicting GEP-NET Prognosis with Nuclear Imaging

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

In this study, correlation analysis between nuclear imaging findings and efficacy outcomes was not preplanned. Considering the potential relevance of nuclear imaging in predicting the prognosis of patients with GEP-NETs,¹⁹ (link)
post hoc analysis was carried out for patients who underwent nuclear imaging (Gallium 68-DOTATOC [⁶⁸Ga-DOTATOC] and/or 18F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) before treatment. Briefly, ⁶⁸Ga-DOTATOC and ¹⁸F-FDG PET/CT images from the vertex to the upper thigh were acquired approximately 60 min after intravenous administration of ⁶⁸Ga-DOTATOC 148 MBq (4 mCi) and ¹⁸F-FDG 0.14 mCi/kg, respectively (GE Discovery PET/CT 690, 690 Elite, or 710; GE Medical Systems, Milwaukee, WI). Maximum standardized uptake values (SUV_max) of the parametric PET images generated by the imaging software, as well as Krenning scores,²⁰ (link) were reviewed by a nuclear medicine physician (YK).

Jeong H., Shin J., Jeong J.H., Kim K.P., Hong S.M., Kim Y.I., Ryu J.S., Ryoo B.Y, & Yoo C. (2021). Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study. ESMO Open, 6(3), 100119.

+ Open protocol

+ Expand

Standardized PET/CT Imaging Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

All patients fasted for at least 6 hours before PET/CT scanning. The plasma glucose level measured before ¹⁸F-FDG injection was <150 mg/dL in all patients. ¹⁸F-FDG was intravenously administered at a dose of 5.18 MBq/kg (range, 114.3–488.4 MBq); 1 hour after ¹⁸F-FDG administration, PET/CT scanning was performed with different systems (Discovery PET/CT 690, 690 Elite, 710; GE Healthcare; Biograph 40 TruePoint PET/CT; Siemens). First, low-dose CT acquisition was performed from the skull base to the upper thigh using the following parameters: 120 kVp, automatic mA, 40 mm collimation, and 3.75 mm thickness for the GE Healthcare machines; 120 kVp, CARE Dose 4D, 28.8 mm collimation, and 5.0 mm thickness for the Siemens machine. A PET scan of the same area was acquired after the CT scan in the 3-dimensional mode with 6 to 7 beds (2 and 2.5 minutes per bed position on the GE Healthcare and Siemens machines, respectively). Images were corrected for attenuation and reconstructed using the 3-dimensional ordered subset expectation maximization (OSEM) method with time-of-flight (TOF) and point-spread-function (PSF) algorithms (192 × 192 matrix, 4 iterations, 18 subsets, 4 mm postsmoothing on GE Healthcare; 168 × 168 matrix, 3 iterations, 21 subsets, 3 mm postsmoothing on Siemens).

Choi S., Kim Y.I., Lee G.D., Choi S., Kim H.R., Kim Y.H., Kim D.K., Park S.I, & Ryu J.S. (2022). Diagnostic value of 18F-FDG PET/CT in discriminating between benign and malignant lesions of the ribs. Medicine, 101(27), e29867.

+ Open protocol

+ Expand

PET/CT Imaging of [18F]FES and [18F]FDG

Check if the same lab product or an alternative is used in the 5 most similar protocols

The production of [¹⁸F]FES was described previously [33 (link)]. PET/CT imaging was performed from the skull base to upper thigh using a Discovery PET/CT 690 or 710 scanner (GE Healthcare), 80–100 min after intravenous injection of 111–222 MBq (3–6 mCi) of [¹⁸F]FES [31 (link)]. PET/CT images were reconstructed using the manufacturer-provided iterative algorithm with 4 iterations and 18 subsets.
[¹⁸F]FDG PET/CT images were obtained from the skull base-to-upper thigh using one of several different PET/CT scanners (Biograph Sensation 16 or Biograph TruePoint 40, Siemens Healthineers; or Discovery PET/CT 690, 690 Elite, or 710, GE Healthcare), 50–70 min after intravenous injection of 5.2–7.4 MBq/kg (0.14–0.2 mCi/kg) of [¹⁸F]FDG as described in a previous report [34 (link)].

Chae S.Y., Son H.J., Lee D.Y., Shin E., Oh J.S., Seo S.Y., Baek S., Kim J.Y., Na S.J, & Moon D.H. (2020). Comparison of diagnostic sensitivity of [18F]fluoroestradiol and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for breast cancer recurrence in patients with a history of estrogen receptor-positive primary breast cancer. EJNMMI Research, 10, 54.

+ Open protocol

+ Expand

Protocol for [68Ga]Ga-DOTA-TOC PET/CT Imaging

Check if the same lab product or an alternative is used in the 5 most similar protocols

For [⁶⁸Ga]Ga-DOTA-TOC PET/CT imaging, 171.7 ± 26.8 MBq (4.6 ± 0.7 mCi) of [⁶⁸Ga]Ga-DOTA-TOC was administered intravenously. After 61 ± 5 min, PET/CT imaging was performed using PET/CT scanners (GE Discovery PET/CT 690, 690 Elite, or 710; GE Medical Systems, Milwaukee, WI, USA) from the vertex to the upper thigh. CT imaging was initially done for the determination of the attenuation map and lesion localization (120 kVp, auto mA, 0.5 rotation time, 3.75-mm slice thickness). Following this, PET imaging was done in three-dimensional mode (3-min emission per bed position, 500-mm field of view). Images were reconstructed via three-dimensional iterative reconstruction using the VPFX-S algorithm (4 iterations, 18 subsets, 4.0-mm field width at half maximum, 192 × 192 matrix). Parametric PET images showing standardized uptake values (SUVs) based on patient body weight were generated.

Kim Y.I., Yoo C., Oh S.J., Lee S.J., Kang J., Hwang H.S., Hong S.M., Ryoo B.Y, & Ryu J.S. (2020). Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours. EJNMMI Research, 10, 63.

+ Open protocol

+ Expand

Optimized 68Ga-PSMA PET/CT Imaging Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

All ⁶⁸Ga-PSMA PET/CT scans were performed before the prostate biopsy. A ⁶⁸Ga-PSMA-617 of 3.7 − 4.44 MBq/kg was administered to each patient. Scans were performed sequentially 40 ± 10 min later using a PET/CT scanner (General Electric Healthcare, 690 Elite, Waukesha, WI, USA). The detailed mpMRI and PET/CT protocols were described in our previous study [18 (link)].
PET/CT images were independently evaluated by two nuclear medicine physicians who were blinded to the pathology and other clinical findings. The negative lesions were defined as follows (a) no dominant intraprostatic activity; (b) diffuse transition zone activity or symmetrical central zone activity that does not extend to the prostate margin on CT. The positive lesions were defined as follows (a) focal transition zone activity visually twice above background; (b) focal peripheral zone activity (no minimum intensity); (c) intense uptake (visual very high intensity or maximal standardized uptake value [SUVmax] > 12) [19 (link)]. The SUVmax of all suspicious lesions and the prostate gland background for negative patients were measured. The dominant lesion SUVmax was recorded for further analysis.

Yang J., Li J., Xiao L., Zhou M., Fang Z., Cai Y., Tang Y, & Hu S. (2023). 68Ga-PSMA PET/CT-based multivariate model for highly accurate and noninvasive diagnosis of clinically significant prostate cancer in the PSA gray zone. Cancer Imaging, 23, 81.

+ Open protocol

+ Expand

Synthesis and Evaluation of 68Ga-DOTATOC PET/CT Imaging

Check if the same lab product or an alternative is used in the 5 most similar protocols

The ⁶⁸Ga-DOTATOC was manually synthesized with a ⁶⁸Ge/⁶⁸Ga generator (iThemba LABS, South Africa) and GMP grade DOTATOC (ABX, Germany) in the cyclotron laboratory of our institution^{24 (link),25 (link)}. Quality control was performed according to European Pharmacopeia; the synthesized ⁶⁸Ga-DOTATOC satisfied all quality control criteria and the radiochemical purity of the ⁶⁸Ga-DOTATOC was 98.2 ± 1.0%, as measured by HPLC. We injected a median dose of 4.65 mCi (range 3.4–5.4) ⁶⁸Ga-DOTATOC, intravenously, in non-fasting patients. Sixty minutes after injection, PET/CT images were generated using the GE Discovery 690, 710, or 690 Elite systems. We acquired the emission PET scans at 3.5 min per bed. Nine patients underwent whole-body PET/CT from skull vertex to both feet. Three patients had torso PET/CT scan from the skull vertex to the proximal thigh. The lesion detectability and SUV_max, normalized to body weight, were determined. Additionally, we compared the ⁶⁸Ga-DOTATOC PET/CT results with the outcomes of clinical/imaging surveillance and/or pathology.

Lee D.Y., Lee S.H., Kim B.J., Kim W., Yoon P.W., Lee S.J., Oh S.J., Koh J.M, & Ryu J.S. (2021). Usefulness of 68Ga-DOTATOC PET/CT to localize the culprit tumor inducing osteomalacia. Scientific Reports, 11, 1819.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!